Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

New Drug Could Treat Trio Of Deadly Parasitic Infectious Diseases

XTALKS VITALS NEWS

Sleeping sickness – or Human African trypanosomiasis – is caused by infection with the Trypanosoma brucei parasite, which is transmitted by the tsetse fly. .

Tweetables from this article:

Tweet: New drug could treat three parasitic infections including, Chagas disease, leishmaniasis and sleeping sickness http://ctt.ec/l4U6t+New drug could treat three parasitic infections including, Chagas disease, leishmaniasis and sleeping sickness.

Tweet: GNF6702 drug acts on proteasomes, which allow the parasites to break down proteins and reuse their components http://ctt.ec/yld3R+GNF6702 drug acts on proteasomes, which allow the parasites to break down proteins and reuse their components.

Share this!

August 10, 2016 | by Sarah Massey, M.Sc.

A new proteasome inhibitor drug could effectively treat three parasitic infections including, Chagas disease, leishmaniasis and sleeping sickness. As described in an article in the journal Nature, the researchers screened three million compounds made by pharmaceutical company Novartis, to identify the most effective, broad-spectrum antiparasitic drugs.

All three diseases are caused by similar parasites, leading the researchers to believe that a single active pharmaceutical ingredient could be able to target them all. Sleeping sickness – or Human African trypanosomiasis – is caused by infection with the Trypanosoma brucei parasite, which is transmitted by the tsetse fly.

Chagas disease is caused by the Trypansosoma cruzi parasite, which is most common in Latin America. Leishmaniasis is spread by the sandfly, and is caused by parasites of the same name. It’s estimated that 20 million people are infected by the three parasites combined, which kill 50,000 people annually.

Currently-available drugs can treat these infections, however they are expensive and require specialized equipment, such as an intravenous drip, which are often unavailable in poorer regions. The new drug identified by researchers – named GNF6702 – was successful at treating all three parasitic infections in mouse models.



“What makes it special is the fact it is targeting all three parasites. That's the first time it has been done, so it is quite special,” Dr. Elmarie Myburgh, a researcher at the University of York, told BBC News. “To me this is obviously a big deal, I'm in this field to try and make a difference, to get to a cure, and we're working hard in the hope that it gets to patients. There's been very little incentive to spend a lot of money on these diseases as they affect a very poor, and yet large, population.”

GNF6702 acts on the protein complexes, known as proteasomes, which allow the parasites to break down proteins and reuse their components. Luckily, this compound does not affect the same protein complexes found in human cells.

According to Richard Glynne, from the Genomics Institute of the Novartis Research Foundation, identifying the proteasome as a drug target was “not by design, more by serendipity.” However, Glynne told BBC News that the drug candidate could eventually be developed into three separate pharmaceuticals, each specifically designed to treat the different parasitic infections.

“It may be a single drug for all three diseases may not be the best strategy,” said Glynne. “The biology of the diseases is different. For example in sleeping sickness the parasite is in the brain, so you need a drug that gets into the brain, so there are tweaks that may be required.”

The researchers are now conducting safety studies to determine the drug’s suitability for human clinical trials. “This is quite an important piece of research, I'm excited by it, but there's still a long way to go,” Dr. Stephen Caddick, the director of innovation at the Wellcome Trust research charity, told BBC News.


Keywords: Drug Target, Parasite, Infectious Disease


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Exclusion Criteria for Clinical Trials Poses Major Barrier to Patient Enrollment

August 17, 2017 - UT Southwestern researchers say that clinical investigators continue to increase the number of exclusion criteria, preventing more patients from participating in clinical trials.

Featured In: Clinical Trials News


Targeting Cellular Nitrogen Metabolism Could Offer a New Treatment for Pancreatic Cancer

August 17, 2017 - An enzyme involved in regulating the amount of nitrogen in the cell could be a new drug target for pancreatic cancer, according to researchers from Boston Children's Hospital and the Broad Institute of MIT and Harvard.

Featured In: Life Science News


Regeneron’s Drug for Respiratory Syncytial Virus Fails in Phase III Clinical Trial

August 16, 2017 - Biotechnology company Regeneron has announced it will not continue development of its antibody drug, suptavumab, after a failure in a Phase III clinical trial.

Featured In: Clinical Trials News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

One Patient’s Perspective on Clinical Trials

REGISTER FOR THESE WEBINARS

Planning and Conducting Trials of the Latest Immunotherapies


ISO 13485:2016 for Medical Device Manufacturers: Ensuring a Smooth Transition through Effective Preparation


Medical Devices: Reviewing Regulatory Changes in the US and EU


Moving Beyond Regulatory and Performance Metrics in Starting Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.